Viatris believes its pipeline of ten complex injectables currently under regulatory review, including seven first-to-market opportunities already filed, represents an opportunity of at least $1bn in peak net sales during the upcoming ‘second phase’ of the firm’s strategic road map beginning in 2024.
The company’s projections came as management admitted during Viatris’ third-quarter earnings call that the firm would miss by $75m its target of $600m in revenues from new
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?